"Pure speculation but it is possible that AMRNs drug Vascepa might cause its CVS effects by epigenetic mechanisms. It affects a broad spectrum of antiiflamatory and other markers" 

Yes, omega-3 polyunsaturated fatty acids (PUFA) like EPA and DHA are known to elicit anti-inflammatory effects. But omega-3 PUFAs elicit many other beneficial changes that may contribute to the overall cardioprotective effect of Vascepa. It is very difficult to say how much of the cardioprotective effect of Vascepa is due to its anti-inflammatory effects. In REDUCE-IT, hsCRP was lower in the Vascepa-treated group compared to the placebo (mineral oil)-treated group. However, this was mainly due to the placebo hsCRP values increasing by about 30% from their starting baseline values; Vascepa lowered hsCRP below the baseline values by a modest ~13%. There are other markers of inflammation other than hsCRP, but that is the only one reported in REDUCE-IT.

Epigenetics is a broad term involving many different types of modifications. Epigenetic changes are a part of normal development, can occur in both healthy and diseased states, and are also dynamically responsive to environmental and physiological stimuli. It would not be surprising to me if these omega-3 PUFAs elicit epigenetic changes. Do you have any references on omega-3 PUFAs affecting DNA methylation or lysine acetylation pattern of histones, and even better any Vascepa/EPA/icosapent ethyl specific references?

"......and its antimitotic effects are now known to be due to epigenetic change as a result of DNA methylation."

I've been following the Vascepa story fairly closely but I may have missed this. Can you provide more detail, preferably with references, to better describe these antimitotic effects of Vascepa or other omega-3 PUFAs?

BearDownAZ